Oncopeptides announces that PEPAXTO® is now included in the NCCN Clinical Practice Guidelines.
Melphalan Flufenamide (PEPAXTO®) is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma Version 6.2021 – April 12, 2021 Category 2A1 Definitions for National Comprehensive Cancer Network® (NCCN®) Categories: Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. For more […]